Literature DB >> 9353041

Detoxification of the Helicobacter pylori cytotoxin.

R Manetti1, P Massari, M Marchetti, C Magagnoli, S Nuti, P Lupetti, P Ghiara, R Rappuoli, J L Telford.   

Abstract

Treatment of the Helicobacter pylori vacuolating cytotoxin with very low concentrations of formaldehyde resulted in abrogation of toxic activity in both a HeLa cell vacuolation assay and an in vivo assay of gastric epithelial damage. Detoxification had only a minimal effect on the integrity of the oligomeric or monomeric structure. The toxoid retained the ability to bind to target cells and to induce high-titer neutralizing antibodies after immunization of rabbits. Furthermore, oral immunization of mice with the toxoid resulted in protection against infective challenge with mouse-adapted strains of H. pylori. The sensitivity of the toxin to formaldehyde treatment suggests that a few lysine residues in the protein may be essential for toxic activity and that VacA detoxified in this manner may be a potential candidate for inclusion in a vaccine against H. pylori infection and disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9353041      PMCID: PMC175662          DOI: 10.1128/iai.65.11.4615-4619.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

Review 1.  Towards third-generation whooping cough vaccines.

Authors:  R Rappuoli; M Pizza; A Podda; M T De Magistris; L Nencioni
Journal:  Trends Biotechnol       Date:  1991-07       Impact factor: 19.536

2.  Labeling of proteins by reductive methylation using sodium cyanoborohydride.

Authors:  N Jentoft; D G Dearborn
Journal:  J Biol Chem       Date:  1979-06-10       Impact factor: 5.157

Review 3.  Reductive alkylation of proteins.

Authors:  G E Means; R E Feeney
Journal:  Anal Biochem       Date:  1995-01-01       Impact factor: 3.365

Review 4.  Toxin inactivation and antigen stabilization: two different uses of formaldehyde.

Authors:  R Rappuoli
Journal:  Vaccine       Date:  1994-05       Impact factor: 3.641

5.  Low pH activates the vacuolating toxin of Helicobacter pylori, which becomes acid and pepsin resistant.

Authors:  M de Bernard; E Papini; V de Filippis; E Gottardi; J Telford; R Manetti; A Fontana; R Rappuoli; C Montecucco
Journal:  J Biol Chem       Date:  1995-10-13       Impact factor: 5.157

6.  Role of the Helicobacter pylori virulence factors vacuolating cytotoxin, CagA, and urease in a mouse model of disease.

Authors:  P Ghiara; M Marchetti; M J Blaser; M K Tummuru; T L Cover; E D Segal; L S Tompkins; R Rappuoli
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

7.  Bafilomycin A1 inhibits Helicobacter pylori-induced vacuolization of HeLa cells.

Authors:  E Papini; M Bugnoli; M De Bernard; N Figura; R Rappuoli; C Montecucco
Journal:  Mol Microbiol       Date:  1993-01       Impact factor: 3.501

8.  Development of a mouse model of Helicobacter pylori infection that mimics human disease.

Authors:  M Marchetti; B Aricò; D Burroni; N Figura; R Rappuoli; P Ghiara
Journal:  Science       Date:  1995-03-17       Impact factor: 47.728

9.  Computer modelling of the NAD binding site of ADP-ribosylating toxins: active-site structure and mechanism of NAD binding.

Authors:  M Domenighini; C Montecucco; W C Ripka; R Rappuoli
Journal:  Mol Microbiol       Date:  1991-01       Impact factor: 3.979

10.  Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease.

Authors:  J L Telford; P Ghiara; M Dell'Orco; M Comanducci; D Burroni; M Bugnoli; M F Tecce; S Censini; A Covacci; Z Xiang
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

View more
  8 in total

1.  Mutational analysis of the Helicobacter pylori vacuolating toxin amino terminus: identification of amino acids essential for cellular vacuolation.

Authors:  D Ye; S R Blanke
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

2.  Binding of the Helicobacter pylori vacuolating cytotoxin to target cells.

Authors:  P Massari; R Manetti; D Burroni; S Nuti; N Norais; R Rappuoli; J L Telford
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

3.  A conventional beagle dog model for acute and chronic infection with Helicobacter pylori.

Authors:  G Rossi; M Rossi; C G Vitali; D Fortuna; D Burroni; L Pancotto; S Capecchi; S Sozzi; G Renzoni; G Braca; G Del Giudice; R Rappuoli; P Ghiara; E Taccini
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

4.  Role of activated protein C in Helicobacter pylori-associated gastritis.

Authors:  S Oka; E C Gabazza; Y Taguchi; M Yamaguchi; S Nakashima; K Suzuki; Y Adachi; I Imoto
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

5.  Clearance of Helicobacter pylori Infection and Resolution of Postimmunization Gastritis in a Kinetic Study of Prophylactically Immunized Mice.

Authors:  Christine A Garhart; Raymond W Redline; John G Nedrud; Steven J Czinn
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

6.  Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters.

Authors:  P J Giannasca; Z X Zhang; W D Lei; J A Boden; M A Giel; T P Monath; W D Thomas
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

Review 7.  Pleiotropic cytotoxicity of VacA toxin in host cells and its impact on immunotherapy.

Authors:  Farnaz Fahimi; Mohammad Reza Tohidkia; Mehdi Fouladi; Reza Aghabeygi; Naser Samadi; Yadollah Omidi
Journal:  Bioimpacts       Date:  2017-03-30

Review 8.  Use of VacA as a Vaccine Antigen.

Authors:  Mati Moyat; Dominique Velin
Journal:  Toxins (Basel)       Date:  2016-06-08       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.